logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Melanoma: nivolumab/ipilimumab yields durable OS benefit in CheckMate 067

4-year data from the phase 3 trial support nivolumab with or without ipilimumab.